{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T07:10:17Z","timestamp":1737270617453,"version":"3.33.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,31]]},"DOI":"10.1097\/qad.0b013e3281338384","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T09:00:32Z","timestamp":1184317232000},"page":"1503-1506","source":"Crossref","is-referenced-by-count":6,"title":["A new approach for \u2018deep salvage\u2019 trials in advanced HIV infection"],"prefix":"10.1097","volume":"21","author":[{"given":"Michael M","family":"Lederman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir\u2013ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"R2-1-20210130","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-1-20210130","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-1-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qai.0000233308.82860.2f","article-title":"Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients","volume":"43","author":"DeJesus","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-1-20210130","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat Meds"},{"key":"R6-1-20210130","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"R7-1-20210130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1086\/315867","article-title":"Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359","volume":"182","author":"Gulick","year":"2000","journal-title":"J Infect Dis"},{"key":"R8-1-20210130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.288.2.169","article-title":"Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial","volume":"288","author":"Hammer","year":"2002","journal-title":"JAMA"},{"key":"R9-1-20210130","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","article-title":"Treatment of antiretroviral-drug-resistant HIV-1 infection","volume":"362","author":"Deeks","year":"2003","journal-title":"Lancet"},{"key":"R10-1-20210130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(04)16589-6","article-title":"Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes","volume":"364","author":"Ledergerber","year":"2004","journal-title":"Lancet"},{"key":"R11-1-20210130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000131310.52526.c7","article-title":"The prevalence of antiretroviral drug resistance in the United States","volume":"18","author":"Richman","year":"2004","journal-title":"AIDS"},{"key":"R12-1-20210130","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/aid.2006.22.1106","article-title":"Drug development strategies for salvage therapy: conflicts and solutions","volume":"22","author":"De Gruttola","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R13-1-20210130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.aids.0000168968.34810.ca","article-title":"Antiretroviral therapies for treatment-experienced patients: current status and research challenges","volume":"19","author":"Struble","year":"2005","journal-title":"AIDS"},{"key":"R14-1-20210130","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1128\/JVI.00712-06","article-title":"Genotypic changes in human immunodeficiency virus-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir","volume":"80","author":"Baxter","year":"2006","journal-title":"J Virol"},{"key":"R15-1-20210130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/135965350200700305","article-title":"Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir\/ritonavir therapy","volume":"7","author":"Kempf","year":"2002","journal-title":"Antivir Ther"},{"key":"R16-1-20210130","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/01.aids.0000194131.43382.19","article-title":"Limited positive predictive value of resistance testing in treatment-experienced patients","volume":"19","author":"Miralles","year":"2005","journal-title":"AIDS"},{"key":"R17-1-20210130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1310\/0XH7-F2V2-1K0R-NU2W","article-title":"Prognostic staging of extensively pretreated patients with advanced HIV-1 disease","volume":"6","author":"Montaner","year":"2005","journal-title":"HIV Clin Trials"},{"key":"R18-1-20210130","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1086\/422692","article-title":"Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects","volume":"190","author":"Swanstrom","year":"2004","journal-title":"J Infect Dis"},{"key":"R19-1-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/135965350601100308","article-title":"A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide","volume":"11","author":"Beatty","year":"2006","journal-title":"Antivir Ther"},{"key":"R21-1-20210130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"R22-1-20210130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1086\/515591","article-title":"Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315","volume":"178","author":"Lederman","year":"1998","journal-title":"J Infect Dis"},{"key":"R23-1-20210130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/339014","article-title":"Safety and antiviral activity at 48 weeks of lopinavir\/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients","volume":"185","author":"Benson","year":"2002","journal-title":"J Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200707310-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:52:35Z","timestamp":1737269555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200707310-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3281338384","relation":{},"ISSN":["0269-9370"],"issn-type":[{"type":"print","value":"0269-9370"}],"subject":[],"published":{"date-parts":[[2007,7,31]]}}}